DB11805 (Saracatinib), is a Src/Abl kinase inhibitor for cancer therapy, has shown promise in AD by targeting Fyn kinase and improving cognitive outcomes at lower doses than used in cancer therapy [108]. Here, SRC is linked to cancer.